Full-Time

Executive Quality Control

Quality Assurance and Control

Posted on 9/16/2025

Deadline 9/30/25
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

No salary listed

Goa, India

In Person

Category
Lab & Research (2)
,
Requirements
  • Bachelor's degree with any years of experience, or an Associate's degree with 4 years of relevant experience, or a high school diploma (or equivalent) and 6 years of relevant experience
  • Demonstrated technical skills in method validation and testing
  • Ability to read and understand applicable compendial methods, Standard Operating Procedures, technical procedures, and governmental regulations
  • Knowledge of Good Manufacturing Practices and its application standards, processes, and policies.
  • Excellent organizational skills and strong ability to multi-task
  • Strong written and verbal communication skills
  • Proficiency with unique Quality Control instruments to meet accuracy specifications for sample management, retains management, interpretation, and evaluation
Responsibilities
  • Perform routine and non-routine analysis of raw materials, in-process samples, and finished products.
  • Independently operate and maintain analytical instruments including UV-Vis Spectrophotometer, IR Spectrometer, HPLC, TLC, Photodocumentation System, and Tiamo System.
  • Execute dissolution testing techniques and interpret results accurately.
  • Troubleshoot and resolve analytical issues, especially related to HPLC systems.
  • Ensure timely planning and execution of QC activities.
  • Escalate issues promptly to relevant stakeholders to avoid delays in production or release.
  • Perform data calculations with precision and ensure accurate documentation.
  • Maintain compliance with GMP, GLP, and other regulatory standards.
  • Participate in method development and validation activities.
  • Support audits and inspections by providing necessary documentation and explanations.
  • Perform sampling and labeling of materials as per defined procedures and verify all equipment and instruments.
  • Interpret and evaluate data for accuracy, precision, trends, and potential cGMP impact, recommending appropriate corrective actions.
  • Ensure all documentation and quality records comply with Good Manufacturing Practices and Good Laboratory Practices and are filed according to existing policies.
  • Review and revise Standard Operating Procedures, analytical methods, and related documents to keep them current.
  • Conduct analyses on finished products, raw materials, and components, including data entry, review, and approval in a computerized database, and generate EMS reports.
  • Contribute to the completion of complex projects, manage time effectively to meet targets, and develop plans for work activities within a team, while exercising judgment with reliance on supervisor and working under their direction.
Desired Qualifications
  • Experience with laboratory work, particularly using analytical HPLC (High Pressure Liquid Chromatography) techniques
  • Proven track record in leading continuous improvement projects
  • Strong knowledge of lean manufacturing principles, six sigma methodologies, and statistical analysis
  • Strong problem-solving skills and attention to detail
  • Ability to manage multiple priorities and meet deadlines.
  • Excellent interpersonal skills and the ability to communicate effectively with colleagues at all levels
  • Adaptability and willingness to learn new techniques and procedures

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Oncology biosimilars grow 52% operationally in Q1 2026 amid high-margin expansion.
  • ELREXFIO Phase 3 data supports earlier multiple myeloma treatment positioning.
  • PF-08653944 advances to 10 Phase 3 trials in 2026 with 9.6mg dose.

What critics are saying

  • Eliquis patent expires 2028, generics erode $6B annual revenue 70% in 12 months.
  • Ibrance generics launch 2027, slash $5B sales 60-80% within 18 months.
  • Danuglipron discontinued April 2025 after liver injury in early trials.

What makes Pfizer unique

  • VEPPANU secures FDA approval as first PROTAC therapy for ESR1-mutated breast cancer.
  • VYNDAMAX patent settlements extend US exclusivity to June 2031.
  • PF-08653944 achieves 12.3% placebo-adjusted weight loss monthly in Phase 2b VESPER-3.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Company News

Pfizer
May 4th, 2026
Esperion Therapeutics Completes $22.75 M Series A Financing | Pfizer

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich

Yahoo Finance
Apr 9th, 2026
Pfizer beats Q4 revenue estimates by 5.5% as branded pharma sector faces mixed earnings

Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.

Yahoo Finance
Apr 7th, 2026
Pfizer stock seen as undervalued buy despite pipeline growth and strategic acquisitions

Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.

Yahoo Finance
Apr 6th, 2026
Pfizer shares climb 7.1% in six months as organic revenue grows 10.1% annually

Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.

Yahoo Finance
Mar 30th, 2026
Pfizer shares up 25% since Jim Cramer said 'pass' on Mad Money

Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.

INACTIVE